JP5809296B2 - 抗真菌薬及びそれらの使用 - Google Patents

抗真菌薬及びそれらの使用 Download PDF

Info

Publication number
JP5809296B2
JP5809296B2 JP2013556894A JP2013556894A JP5809296B2 JP 5809296 B2 JP5809296 B2 JP 5809296B2 JP 2013556894 A JP2013556894 A JP 2013556894A JP 2013556894 A JP2013556894 A JP 2013556894A JP 5809296 B2 JP5809296 B2 JP 5809296B2
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
compound
integer
composition according
formulated
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2013556894A
Other languages
English (en)
Japanese (ja)
Other versions
JP2014516339A5 (enExample
JP2014516339A (ja
Inventor
ジェイムス，ケネス，デューク，ジュニア
ラウデマン，クリストファー，パトリック
マルカー，ナヴディープ，バルクリシュナ
ラダクリシュナン，バラシンガム
Original Assignee
シーチェイド ファーマシューティカルズ，インコーポレーテッド
シーチェイド ファーマシューティカルズ，インコーポレーテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by シーチェイド ファーマシューティカルズ，インコーポレーテッド, シーチェイド ファーマシューティカルズ，インコーポレーテッド filed Critical シーチェイド ファーマシューティカルズ，インコーポレーテッド
Publication of JP2014516339A publication Critical patent/JP2014516339A/ja
Publication of JP2014516339A5 publication Critical patent/JP2014516339A5/ja
Application granted granted Critical
Publication of JP5809296B2 publication Critical patent/JP5809296B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/50—Cyclic peptides containing at least one abnormal peptide link
    • C07K7/54—Cyclic peptides containing at least one abnormal peptide link with at least one abnormal peptide link in the ring
    • C07K7/56—Cyclic peptides containing at least one abnormal peptide link with at least one abnormal peptide link in the ring the cyclisation not occurring through 2,4-diamino-butanoic acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/64—Cyclic peptides containing only normal peptide links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/02—Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/50—Cyclic peptides containing at least one abnormal peptide link
    • C07K7/54—Cyclic peptides containing at least one abnormal peptide link with at least one abnormal peptide link in the ring
    • C07K7/60—Cyclic peptides containing at least one abnormal peptide link with at least one abnormal peptide link in the ring the cyclisation occurring through the 4-amino group of 2,4-diamino-butanoic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/50—Cyclic peptides containing at least one abnormal peptide link
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/50—Cyclic peptides containing at least one abnormal peptide link
    • C07K7/54—Cyclic peptides containing at least one abnormal peptide link with at least one abnormal peptide link in the ring

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Dermatology (AREA)
  • Hematology (AREA)
  • Otolaryngology (AREA)
  • Urology & Nephrology (AREA)
  • Reproductive Health (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
JP2013556894A 2011-03-03 2012-03-02 抗真菌薬及びそれらの使用 Active JP5809296B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161448807P 2011-03-03 2011-03-03
US61/448,807 2011-03-03
PCT/US2012/027451 WO2012119065A2 (en) 2011-03-03 2012-03-02 Antifungal agents and uses thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2015178029A Division JP6111447B2 (ja) 2011-03-03 2015-09-10 抗真菌薬及びそれらの使用

Publications (3)

Publication Number Publication Date
JP2014516339A JP2014516339A (ja) 2014-07-10
JP2014516339A5 JP2014516339A5 (enExample) 2015-05-14
JP5809296B2 true JP5809296B2 (ja) 2015-11-10

Family

ID=46758514

Family Applications (4)

Application Number Title Priority Date Filing Date
JP2013556894A Active JP5809296B2 (ja) 2011-03-03 2012-03-02 抗真菌薬及びそれらの使用
JP2015178029A Active JP6111447B2 (ja) 2011-03-03 2015-09-10 抗真菌薬及びそれらの使用
JP2017026954A Active JP6302108B2 (ja) 2011-03-03 2017-02-16 抗真菌薬及びそれらの使用
JP2018036159A Pending JP2018118977A (ja) 2011-03-03 2018-03-01 抗真菌薬及びそれらの使用

Family Applications After (3)

Application Number Title Priority Date Filing Date
JP2015178029A Active JP6111447B2 (ja) 2011-03-03 2015-09-10 抗真菌薬及びそれらの使用
JP2017026954A Active JP6302108B2 (ja) 2011-03-03 2017-02-16 抗真菌薬及びそれらの使用
JP2018036159A Pending JP2018118977A (ja) 2011-03-03 2018-03-01 抗真菌薬及びそれらの使用

Country Status (21)

Country Link
US (6) US8722619B2 (enExample)
EP (2) EP3192803B1 (enExample)
JP (4) JP5809296B2 (enExample)
CN (2) CN106279369B (enExample)
CA (2) CA3053850A1 (enExample)
CY (2) CY1119709T1 (enExample)
DK (1) DK2680873T3 (enExample)
ES (1) ES2645074T3 (enExample)
FI (1) FIC20240022I1 (enExample)
FR (1) FR24C1027I2 (enExample)
HR (1) HRP20171579T8 (enExample)
HU (2) HUE036778T2 (enExample)
LT (2) LT2680873T (enExample)
NL (1) NL301280I2 (enExample)
NO (1) NO2680873T3 (enExample)
PL (1) PL2680873T3 (enExample)
PT (1) PT2680873T (enExample)
RS (1) RS56426B1 (enExample)
SI (1) SI2680873T1 (enExample)
SM (1) SMT201700460T1 (enExample)
WO (1) WO2012119065A2 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2017171658A (ja) * 2012-03-19 2017-09-28 シダラ セラピューティクス インコーポレーテッド エキノキャンディン系化合物のための投与レジメン

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NO2680873T3 (enExample) 2011-03-03 2018-01-06
US20160213742A1 (en) * 2013-09-04 2016-07-28 Cidara Therapeutics, Inc. Compositions and methods for the treatment of fungal infections
EP3136864A4 (en) * 2014-04-28 2017-12-27 University of Central Florida Research Foundation, Inc. Compositions, methods of making a composition, and methods of use
WO2016201283A1 (en) * 2015-06-12 2016-12-15 Cidara Therapeutics, Inc. Antifungal agents
US20180256673A1 (en) * 2015-09-16 2018-09-13 Cidara Therapeutics, Inc. Methods for treating fungal infections
CN106674333B (zh) * 2015-11-06 2020-10-27 博瑞生物医药（苏州）股份有限公司 一种环肽类抗真菌化合物及其制备方法
HK1258533A1 (zh) 2016-01-08 2019-11-15 Cidara Therapeutics, Inc. 防止和治疗肺孢子虫感染的方法
CN109154603A (zh) * 2016-03-16 2019-01-04 奇达拉治疗公司 用于治疗真菌感染的给药方案
CN109789193A (zh) 2016-09-13 2019-05-21 普罗瑟拉生物公司 使用间α抑制蛋白治疗肺病的方法
WO2018102407A1 (en) * 2016-11-29 2018-06-07 Cidara Therapeutics, Inc Methods for preventing fungal infections
EP3577129A1 (en) * 2017-01-31 2019-12-11 Cidara Therapeutics, Inc. Methods for treating fungal infections
WO2018200722A1 (en) 2017-04-25 2018-11-01 Prothera Biologics, Inc. Methods for quantifying inter-alpha inhibitor proteins
CN111050798A (zh) * 2017-07-12 2020-04-21 奇达拉治疗公司 用于治疗真菌感染的组合物和方法
US11524980B2 (en) 2018-06-15 2022-12-13 Cidara Therapeutics, Inc. Synthesis of echinocandin antifungal agent
WO2020086931A1 (en) * 2018-10-25 2020-04-30 Cidara Therapeutics, Inc. Polymorph of echinocandin antifungal agent
US12466856B2 (en) 2019-12-06 2025-11-11 Shanghai Senhui Medicine Co., Ltd. Echinocandin analogues and preparation method therefor
WO2022253297A1 (zh) 2021-06-03 2022-12-08 上海森辉医药有限公司 一种阿尼芬净衍生物的制备方法
CN115850383A (zh) * 2022-12-15 2023-03-28 江苏九阳生物制药有限公司 一种雷扎芬净纯化方法
CN116903706B (zh) * 2023-06-13 2024-05-17 深圳市祥根生物有限公司 一种棘白菌素类药物及其制备方法和用途

Family Cites Families (62)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4427660A (en) 1982-03-03 1984-01-24 Research Corporation Formyl-methionyl chemotatic peptide antibiotic conjugates useful in treating infections
US5166135A (en) 1988-09-12 1992-11-24 Merck & Company, Inc. Method for the control of pneumocystis carinii
US6030944A (en) * 1991-10-01 2000-02-29 Merck & Co., Inc. Cyclohexapeptidyl bisamine compounds
US5399552A (en) 1991-10-17 1995-03-21 Merck & Co, Inc Antibiotic peptides bearing aminoalkylthioether moieties
US5378804A (en) 1993-03-16 1995-01-03 Merck & Co., Inc. Aza cyclohexapeptide compounds
US6268338B1 (en) 1993-04-30 2001-07-31 Merck & Co., Inc. Cyclohexapeptidyl amine compounds
US5948753A (en) 1993-05-04 1999-09-07 Merck & Co., Inc. Cyclohexapeptidyl propanolamine compounds
JPH09500103A (ja) * 1993-05-04 1997-01-07 メルク エンド カンパニー インコーポレーテッド シクロヘキサペプチジルアミノアルキルエーテル
AU7874494A (en) * 1993-09-22 1995-04-10 Merck & Co., Inc. Antifungal and anti-pneumocystis compounds, compositions containing such compounds, and methods of use
US5541160A (en) * 1994-04-04 1996-07-30 Merck & Co., Inc. Antifungal and anti-pneumocystis compounds, compositions containing such compounds, and methods of use
US5514651A (en) * 1994-09-16 1996-05-07 Merck & Co., Inc. Aza cyclohexapeptide compounds
US5516756A (en) 1994-10-31 1996-05-14 Merck & Co., Inc. Aza cyclohexapeptide compounds
ES2162039T3 (es) 1995-01-26 2001-12-16 Merck & Co Inc Nuevos ciclohexapeptidos antifungicos.
US5652213A (en) * 1995-05-26 1997-07-29 Eli Lilly And Company Cyclic peptide antifungal agents
AR006598A1 (es) 1996-04-19 1999-09-08 Merck Sharp & Dohme "composiciones anti-fungosas, su uso en la manufactura de medicamentos y un procedimiento para su preparación"
US6069126A (en) 1996-09-12 2000-05-30 Merck & Co., Inc. Antifungal combination therapy
EP1137663B1 (en) * 1998-12-09 2006-08-30 Eli Lilly And Company Purification of echinocandin cyclopeptide compounds
US6248363B1 (en) 1999-11-23 2001-06-19 Lipocine, Inc. Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
PT1582204E (pt) 1999-03-03 2013-11-25 Lilly Co Eli Formulações farmacêuticas de equinocandina que contêm tensioactivos que formam micelas
KR20010112302A (ko) 1999-03-03 2001-12-20 피터 지. 스트링거 제약학적 경구용 ｅｃｂ 조제물 및 조성물의 제조 방법
US6309622B1 (en) 1999-03-26 2001-10-30 Protech Professional Products, Inc. Antimicrobial denture cleansing compositions
EP1172105A4 (en) 1999-04-16 2002-09-04 Fujisawa Pharmaceutical Co ANTIFUNGAL COMPOSITIONS
US6610822B2 (en) 2000-09-01 2003-08-26 Merck & Co., Inc. Purification process
HU0104790D0 (en) 2001-11-08 2002-01-28 Human Rt Pharmaceutical combinations for topical application
US6991800B2 (en) 2002-06-13 2006-01-31 Vicuron Pharmaceuticals Inc. Antifungal parenteral products
WO2005014777A2 (en) 2002-10-16 2005-02-17 Board Of Regents, The University Of Texas System Methods and compositions for increasing the efficacy of biologically-active ingredients
US6913759B2 (en) 2003-03-11 2005-07-05 Curatek Pharmaceuticals Holding, Inc. Gel composition and method for treatment of vaginal infections
WO2005018743A1 (en) 2003-07-22 2005-03-03 Theravance, Inc. Use of an echinocandin antifungal agent in combination with a glycopeptide antibacterial agent
US20060140990A1 (en) 2003-09-19 2006-06-29 Drugtech Corporation Composition for topical treatment of mixed vaginal infections
BRPI0614445B8 (pt) 2005-07-26 2021-07-27 Merck & Co Inc ensaio de ácido nucleico para resistência de fármaco de equinocandina em fungos suscetíveis aos fármacos de equinocandina e contendo o gene fks1 que corresponde a subunidade fks1p 1,3-?-d-glicano sintase, bem como conjunto de oligonucleotídeos e kit de reagentes de amplificação
WO2007113386A1 (en) * 2006-03-31 2007-10-11 Karyon-Ctt Ltd Peptide conjugates
GB0702020D0 (en) 2007-02-02 2007-03-14 Novabiotics Ltd Peptides and their use
US20090238867A1 (en) 2007-12-13 2009-09-24 Scott Jenkins Nanoparticulate Anidulafungin Compositions and Methods for Making the Same
US20100009009A1 (en) 2008-07-10 2010-01-14 Micropure, Inc. Method and composition for prevention and treatment of oral fungal infections
GB0817121D0 (en) 2008-09-18 2008-10-29 Univ St Andrews Anti-fungal therapy
BRPI1008037B1 (pt) 2009-02-25 2019-08-06 Stiefel Research Australia Pty Ltd. Composição de espuma aerossol de emulsão de óleo em água, uso da dita composição para o tratamento de uma doença, distúrbio ou condição da pele e processo para a preparação da dita composição
US9006391B2 (en) * 2009-05-07 2015-04-14 Dsm Sinochem Pharmaceuticals Netherlands B.V. Method for the preparation of cyclopeptides
PL2470168T3 (pl) 2009-08-26 2018-06-29 Bioelectron Technology Corporation Sposoby zapobiegania i leczenia niedokrwienia mózgu
WO2011025875A1 (en) 2009-08-27 2011-03-03 Seachaid Pharmaceuticals, Inc. Echinocandin derivatives
EP2525831B1 (en) 2010-01-22 2019-05-15 Ascendis Pharma A/S Carrier-linked carbamate prodrug linkers
NO2680873T3 (enExample) * 2011-03-03 2018-01-06
EP2739652B1 (en) 2011-08-04 2017-04-05 Medizinische Universität Innsbruck Cahgt1p inhibitors for use in the treatment of candidiasis
US8829053B2 (en) 2011-12-07 2014-09-09 Rochal Industries Llp Biocidal compositions and methods of using the same
HRP20231151T1 (hr) 2012-03-19 2024-01-05 Cidara Therapeutics, Inc. Režimi za doziranje spojeva iz klase ehinokandina
CN102766198A (zh) 2012-05-04 2012-11-07 中国人民解放军第二军医大学 一种糖肽类抗真菌化合物及其制备方法与应用
WO2014113693A1 (en) 2013-01-18 2014-07-24 University Of Utah Research Foundation Modified release osmotic pump for ph-responsive intravaginal drug delivery
WO2014124504A1 (en) 2013-02-13 2014-08-21 Katholieke Universiteit Leuven Ku Leuven Research & Development Compositions and methods for treating biofilms
WO2014145109A1 (en) 2013-03-15 2014-09-18 Arizona Board Of Regents, For And On Behalf Of, Arizona State University Sugar-linker-drug conjugates
CN112656782A (zh) 2013-05-01 2021-04-16 尼奥酷里私人有限公司 治疗细菌感染的方法
US20160213742A1 (en) 2013-09-04 2016-07-28 Cidara Therapeutics, Inc. Compositions and methods for the treatment of fungal infections
US20180256673A1 (en) 2015-09-16 2018-09-13 Cidara Therapeutics, Inc. Methods for treating fungal infections
WO2017049105A1 (en) 2015-09-16 2017-03-23 Cidara Therapeutics, Inc. Formulations for treating fungal infections
HK1258533A1 (zh) 2016-01-08 2019-11-15 Cidara Therapeutics, Inc. 防止和治疗肺孢子虫感染的方法
CN109154603A (zh) 2016-03-16 2019-01-04 奇达拉治疗公司 用于治疗真菌感染的给药方案
CN110290797A (zh) 2016-11-01 2019-09-27 奇达拉治疗公司 用于预防和治疗真菌感染的单剂量方法
WO2018102407A1 (en) 2016-11-29 2018-06-07 Cidara Therapeutics, Inc Methods for preventing fungal infections
EP3577129A1 (en) 2017-01-31 2019-12-11 Cidara Therapeutics, Inc. Methods for treating fungal infections
WO2018187574A1 (en) 2017-04-05 2018-10-11 Cidara Therapeutics, Inc. Compositions and methods for the treatment of fungal infections
WO2018191692A1 (en) 2017-04-14 2018-10-18 Cidara Therapeutics, Inc. Methods for treating fungal infections
CN111050798A (zh) 2017-07-12 2020-04-21 奇达拉治疗公司 用于治疗真菌感染的组合物和方法
AU2018311375A1 (en) 2017-08-03 2020-03-12 Napp Pharmaceutical Group Limited Methods for preventing and treating intra-abdominal candidiasis
US11524980B2 (en) 2018-06-15 2022-12-13 Cidara Therapeutics, Inc. Synthesis of echinocandin antifungal agent

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2017171658A (ja) * 2012-03-19 2017-09-28 シダラ セラピューティクス インコーポレーテッド エキノキャンディン系化合物のための投与レジメン

Also Published As

Publication number Publication date
SI2680873T1 (sl) 2017-12-29
US20170253635A1 (en) 2017-09-07
PL2680873T3 (pl) 2018-01-31
HRP20171579T8 (hr) 2018-12-14
LT2680873T (lt) 2017-11-27
HUS2400021I1 (hu) 2024-07-28
CN106279369A (zh) 2017-01-04
JP2018118977A (ja) 2018-08-02
LTPA2024520I1 (enExample) 2024-07-10
EP2680873A2 (en) 2014-01-08
US12344680B2 (en) 2025-07-01
EP3192803A1 (en) 2017-07-19
US20160075740A1 (en) 2016-03-17
EP2680873B1 (en) 2017-08-09
CY2024022I2 (el) 2025-03-28
CN106279369B (zh) 2020-02-11
HRP20171579T1 (hr) 2018-02-09
CN103889221B (zh) 2016-08-31
WO2012119065A2 (en) 2012-09-07
EP2680873A4 (en) 2015-08-26
CY2024022I1 (el) 2025-03-28
RS56426B1 (sr) 2018-01-31
FIC20240022I1 (fi) 2024-06-19
JP2017132770A (ja) 2017-08-03
CA2865791C (en) 2019-10-08
NO2680873T3 (enExample) 2018-01-06
DK2680873T3 (en) 2017-10-30
PT2680873T (pt) 2017-11-01
CA2865791A1 (en) 2012-09-07
US20130244930A1 (en) 2013-09-19
FR24C1027I1 (fr) 2024-08-30
US8722619B2 (en) 2014-05-13
FR24C1027I2 (fr) 2025-05-23
JP6111447B2 (ja) 2017-04-12
EP3192803B1 (en) 2020-12-09
CA3053850A1 (en) 2012-09-07
ES2645074T8 (es) 2018-09-28
CN103889221A (zh) 2014-06-25
US9217014B2 (en) 2015-12-22
JP2014516339A (ja) 2014-07-10
JP2016029052A (ja) 2016-03-03
ES2645074T3 (es) 2017-12-04
SMT201700460T1 (it) 2018-01-11
CY1119709T1 (el) 2018-06-27
HUE036778T2 (hu) 2018-07-30
US20150024997A1 (en) 2015-01-22
NL301280I2 (nl) 2024-08-01
US20250289852A1 (en) 2025-09-18
JP6302108B2 (ja) 2018-03-28
US20220162263A1 (en) 2022-05-26
US9676821B2 (en) 2017-06-13
WO2012119065A3 (en) 2014-03-13

Similar Documents

Publication Publication Date Title
JP6302108B2 (ja) 抗真菌薬及びそれらの使用
EP0448353A2 (en) Lipopeptide compounds
US20120190613A1 (en) Echinocandin derivatives
WO2016201283A1 (en) Antifungal agents
EP4396196A1 (en) Peptides with antimicrobial activities
CA2080756A1 (en) 1-(4-hydroxy-5-aminoethyloxy-n2- (10,12-dimethyl-1-oxotetraecyl) ornithine)-5(3-hydroxyglutamine) -6-(3-hydroxyproline) echinocandin
HK1232898A1 (en) Antifungal agents and uses thereof
HK1241392B (en) Antifungal agents and uses thereof
HK1241392A1 (en) Antifungal agents and uses thereof
HK1232898B (zh) 抗真菌剂及其应用
HK1193362A (en) Antifungal agents and uses thereof
HK1193362B (en) Antifungal agents and uses thereof
EP1254161B1 (en) Aerothricin analogs, their preparation and use
CN117897394A (zh) 具有抗微生物活性的胜肽

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20141112

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20150302

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20150302

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20150325

A871 Explanation of circumstances concerning accelerated examination

Free format text: JAPANESE INTERMEDIATE CODE: A871

Effective date: 20150325

A975 Report on accelerated examination

Free format text: JAPANESE INTERMEDIATE CODE: A971005

Effective date: 20150413

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20150421

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20150716

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20150811

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20150910

R150 Certificate of patent or registration of utility model

Ref document number: 5809296

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

S111 Request for change of ownership or part of ownership

Free format text: JAPANESE INTERMEDIATE CODE: R313113

S531 Written request for registration of change of domicile

Free format text: JAPANESE INTERMEDIATE CODE: R313531

R350 Written notification of registration of transfer

Free format text: JAPANESE INTERMEDIATE CODE: R350

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

S111 Request for change of ownership or part of ownership

Free format text: JAPANESE INTERMEDIATE CODE: R313113

R350 Written notification of registration of transfer

Free format text: JAPANESE INTERMEDIATE CODE: R350

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250